Skip to Main Content

The YODA ProjectThe YODA Project

    • Welcome
      • Policies
      • Development
      • Due Diligence Assessment
      • Data Use Agreement
      • Data Expiration
    • Project Leadership
    • Steering Committee
    • Roles & Responsibilities
      • Partnering with the YODA Project
        • Overview
        • Available Data
        • Data Release Pilot Project
      • Johnson & Johnson Consumer Inc. (a subsidiary of Kenvue, Inc.)
        • Overview
        • Systematic Reviews
        • Approved Data Requests
      • QMUL
      • SI-BONE
    • Publications & Presentations
    • Announcements & Media Coverage
    • Relevant Literature
      • YODA Project Steering Committee and Stakeholders Conference
      • University College London and YODA Project Joint Meeting on Facilitating Data Access to Non-Industry Funded Research
    • Community Data Sharing Resources
    • FAQs
    • Acknowledgements
    • Contact Us
      • How To
      • Conflict of Interest
      • Data Use Agreement Training
    • Data Request Review Process
    • Request CSR Summary
    • Approved Data Requests
  • Trials
  • My Dashboard
    • YODA Project Metrics
      • Submitted Requests to Use Johnson & Johnson Data
      • Details of Data Requests
      • Clinical Trial Inquiries and CSR Summary Requests
      • Trials Determined to be Unavailable
  • Log in

UPTRAVI®

NCT03078907 – A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient’s Self-reported Symptoms and Their Impacts

Posted on August 5, 2023 by tsuperadmin -

NCT02260557 – A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study to Assess Efficacy and Safety of Selexipag in Adult Subjects With Raynaud’s Phenomenon Secondary to Systemic Sclerosis

Posted on January 28, 2020 by tsuperadmin -

NCT02471183 – Multicenter, Open-label, Single-group Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Adult Patients With Pulmonary Arterial Hypertension

Posted on January 28, 2020 by tsuperadmin -

NCT01106014 – A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension

Posted on October 23, 2018 by tsuperadmin -

Side navigation

Site Map
Yale University logo
CORE - Center for outcomes, research, and evaluation Logo
  • Visit the YODA Project on Facebook
  • Visit the YODA Project on X

Accessibility at Yale

website designed by Gravity Switch